This week, five pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Ocera Therapeutics, Inc. (OCRX) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. For more information, get Portfolio Grader’s complete analysis of OCRX stock.
Johnson & Johnson (JNJ) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. At present, the stock has a dividend yield of 2.6%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
The rating of Bristol-Myers Squibb Company (BMY) moves up this week, rising from a C to a B. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock.
Watson Pharmaceuticals (WPI) gets a higher grade this week, advancing from a B last week to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
This is a strong week for Repros Therapeutics (RPRX). The company’s rating climbs to A from the previous week’s B. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. Shares of RPRX have increased 11.7% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.